Blog
RSS FeedPosted by Michael Wonder on 01 Aug 2018
Canada’s drug agency advised against reimbursing a costly eczema drug — here’s why people are worried
30 July 2018 - Five years ago, Felix Tang’s eczema was a debilitating accompaniment to stress. The chronic inflammatory skin ...
Posted by Michael Wonder on 10 Jul 2018
Sanofi denounces CADTH negative recommendation on Dupixent
10 July 2018 - Sanofi Genzyme said that it is disappointed with the recent recommendation by CADTH to not reimburse Dupixent, ...
Posted by Michael Wonder on 09 Jul 2018
CADTH publishes final CDEC recommendation for dupilumab
9 July 2018 - CADTH has completed its assessment of Dupixent (dupilumab) for the treatment of patients with atopic dermatitis. ...
Posted by Michael Wonder on 13 Mar 2018
Price and clinical factors impact Canadian orphan drug recommendation rates
11 March 2018 - Canada’s Common Drug Review (CDR), which provides recommendations on public payer reimbursement for all non-oncology drugs, ...
Posted by Michael Wonder on 27 Feb 2018
Sobi’s Orfadin (nitisinone) receives positive reimbursement recommendation for the treatment of HT-1 from CADTH Canadian Drug Expert Committee
27 February 2018 - Sobi announced today that the CADTH Canadian Drug Expert Committee has issued a conditional positive reimbursement ...
Posted by Michael Wonder on 07 Feb 2018
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Maviret – an oral therapy for the treatment of patients with hepatitis C
6 February 2018 - Maviret previously received a Notice of Compliance from Health Canada on 16 August 2017. ...
Posted by Michael Wonder on 03 Aug 2017
Sandoz Erelzi (etanercept) receives positive reimbursement recommendation from Common Drug Review for treatment of multiple inflammatory diseases
2 August 2017 - Positive recommendation moves Erelzi closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 29 May 2017
CADTH publishes final recommendations for two Servier medicines
25 May 2017 - CADTH has published outcomes for edoxaban tosylate (Lixiana) and ivabradine hydrochloride (Lancora). ...
Posted by Michael Wonder on 25 May 2017
CADTH recommends reimbursement of Gilead's Odefsey
25 May 2017 - The CADTH Canadian Drug Expert Committee has recommended that emtricitabine/rilpivirine/tenofovir alafenamide be reimbursed as a complete ...
Posted by Michael Wonder on 10 May 2017
Provincial drug plans, including Ontario and BC, make Entyvio (vedolizumab) available to treat inflammatory bowel disease
9 May 2017 - Gut-selective treatment now funded publicly for Canadians with ulcerative colitis and Crohn's disease. ...
Posted by Michael Wonder on 20 Apr 2017
CADTH recommends Kevzara
18 April 2017 - Sarilumab was approved by Health Canada on 12 Jan 2017 for the treatment of adult patients ...
Posted by Michael Wonder on 27 Mar 2017
CADTH recommends Teva's Cinqair
22 March 2017 - Recommendation states price needs to be reduced by 90%. ...
Posted by Michael Wonder on 23 Mar 2017
CADTH recommends reimbursement of Stelara for new indication
21 March 2017 - The cost of treatment with ustekinumab should not exceed the drug plan cost of the least costly ...
Posted by Michael Wonder on 16 Mar 2017
Call for feedback: new drugs for type 2 diabetes: second-line therapy : a therapeutic review update
15 March 2017 - A report on new drugs for second-line therapy for 2 diabetes: a therapeutic review update is now ...
Posted by Michael Wonder on 30 Jan 2017
CADTH recommends UCB's Brivlera
25 January 2017 - CADTH's first outcome for 2017 is in favour of the reimbursement of brivaracetam. ...